Serena Lacerenza1, Federica Ciregia1,2, Laura Giusti3,4, Alessandra Bonotti5, Viviana Greco6,7, Gino Giannaccini1, Vanessa D'Antongiovanni1, Poupak Fallahi5, Luisa Pieroni8, Alfonso Cristaudo5, Antonio Lucacchini4, Maria Rosa Mazzoni9, Rudy Foddis5. 1. Department of Pharmacy, University of Pisa, Pisa, Italy. 2. Department of Rheumatology, GIGA Research, Centre Hospitalier Universitaire (CHU) de Liège, Liège, Belgium. 3. School of Pharmacy, University of Camerino, Camerino, Italy. 4. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 5. Department of Translational Research and New Medical and Surgical Technologies, Occupational Medicine Unit, University-Hospital of Pisa, Pisa, Italy. 6. Institute of Biochemistry and Clinical Chemistry, Università Cattolica del Sacro Cuore, Rome, Italy. 7. Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 8. Proteomics and Metabonomics Unit, IRCCS-Fondazione Santa Lucia, Rome, Italy. 9. Department of Pharmacy, University of Pisa, Pisa, Italy maria.mazzoni@unipi.it.
Abstract
BACKGROUND: Malignant pleural mesothelioma (MPM) a rare neoplasm linked to asbestos exposure is characterized by a poor prognosis. Soluble mesothelin is currently considered the most specific diagnostic biomarker. The aim of the study was to identify novel biomarkers by proteomic analysis of two MPM cell lines secretome. MATERIALS AND METHODS: The protein patterns of MPM cells secretome were examined and compared to a non-malignant mesothelial cell line using two-dimensional gel electrophoresis coupled to mass spectrometry. Serum levels of candidate biomarkers were determined in MPM patients and control subjects. RESULTS: Two up-regulated proteins involved in cancer biology, prosaposin and quiescin Q6 sulfhydryl oxidase 1, were considered candidate biomarkers. Serum levels of both proteins were significantly higher in MPM patients than control subjects. Combining the data of each receiver-operating characteristic analysis predicted a good diagnostic accuracy. CONCLUSION: A panel of the putative biomarkers represents a promising tool for MPM diagnosis. Copyright
BACKGROUND:Malignant pleural mesothelioma (MPM) a rare neoplasm linked to asbestos exposure is characterized by a poor prognosis. Soluble mesothelin is currently considered the most specific diagnostic biomarker. The aim of the study was to identify novel biomarkers by proteomic analysis of two MPM cell lines secretome. MATERIALS AND METHODS: The protein patterns of MPM cells secretome were examined and compared to a non-malignant mesothelial cell line using two-dimensional gel electrophoresis coupled to mass spectrometry. Serum levels of candidate biomarkers were determined in MPM patients and control subjects. RESULTS: Two up-regulated proteins involved in cancer biology, prosaposin and quiescin Q6 sulfhydryl oxidase 1, were considered candidate biomarkers. Serum levels of both proteins were significantly higher in MPM patients than control subjects. Combining the data of each receiver-operating characteristic analysis predicted a good diagnostic accuracy. CONCLUSION: A panel of the putative biomarkers represents a promising tool for MPM diagnosis. Copyright
Authors: P A Zucali; G L Ceresoli; F De Vincenzo; M Simonelli; E Lorenzi; L Gianoncelli; A Santoro Journal: Cancer Treat Rev Date: 2011-02-01 Impact factor: 12.111
Authors: Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman Journal: J Thorac Dis Date: 2013-12 Impact factor: 2.895
Authors: Laura Giusti; Cristina Angeloni; Maria Cristina Barbalace; Serena Lacerenza; Federica Ciregia; Maurizio Ronci; Andrea Urbani; Clementina Manera; Maria Digiacomo; Marco Macchia; Maria Rosa Mazzoni; Antonio Lucacchini; Silvana Hrelia Journal: Int J Mol Sci Date: 2018-08-08 Impact factor: 5.923